Navigation Links
New drug improves progression-free survival, shrinks tumors in rare cancer for first time
Date:6/1/2013

CHICAGO, JUNE 1, 2013 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).

The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare there are only 2,500 cases diagnosed in the United States each year about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.

Researchers found that progression-free survival (PFS) in patients receiving selumetinib was nearly 16 weeks and 50 percent of these patients experienced tumor shrinkage, with 15 percent achieving major shrinkage. Patients receiving temozolomide, the current standard chemotherapy, had seven weeks of PFS and no tumor shrinkage. Selumetinib also lengthened overall survival to 10.8 months versus 9.4 months with temozolomide, and side effects were manageable.

"This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients, who have very limited treatment options," said Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering and lead author on the study. "This clinical benefit has never been demonstrated with other conventional or investigational agents, which is all we have been able to offer patients for decades."

Dr. Carvajal and his team decided to test selumetinib because it blocks the MEK protein, a key component of the tumor-driving MAPK pathway. This pathway is activated by mutations in the Gnaq and Gna11 genes, which occur in more than 85 percent of uveal melanoma patients; 84 percent of patients in this trial had one of the mutations.

Uveal melanoma does not respond to the drugs given to patients with melanoma on the skin; and, in fact, there is no drug approved specifically for treatment of the disease. Patients with uveal melanoma receive surgery to remove the tumor and in some advanced cases, the entire eye as well as radiation therapy or chemotherapy.

In the trial, researchers randomized 98 patients with metastatic uveal melanoma and administered selumetinib to 47, of which 81 percent had a Gnaq or Gna11 mutation. Of the 49 patients who received temozolomide, 86 percent had a mutation. Two patients were not treated. Despite the study's cross-over design meaning patients whose tumors progressed on temozolomide could begin taking selumetinib there was a trend towards improved survival with selumetinib. Selumetinib was generally tolerable, with most side effects manageable with conservative management or dose modification.

Dr. Carvajal is currently planning a confirmatory multi-center, randomized trial that will enroll approximately 100 patients and be led by Memorial Sloan-Kettering. "If we can confirm selumetinib's effectiveness in treating advanced uveal melanoma in this follow-up trial, it will become the standard therapy for this disease, forming a foundation for new drug combinations that could maximize selumetinib's MEK-inhibitor effect," he said. "It could offer a whole new way to treat this historically untreatable disease."


'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
646-227-3956
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Lifeguard Master Improves on its Swim Suite Line
2. Task master: Categorizing rewards improves motivation
3. Study shows longer treatment for children with langerhans cell hystiocytosis improves survival rates
4. Levosimendan improves event free survival by 50 percent in end-stage heart failure
5. New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance
6. New smartphone application improves colonoscopy preparation
7. Cognitive training improves executive function in breast cancer survivors
8. Study Shows Dual Targeting of HER2 and HR-positive Metastatic Breast Cancer Improves Survival Rates
9. North Shore-LIJ's New Image Fusion-Guided Biopsy Improves Accuracy of Prostate Cancer Diagnosis
10. Carnegie Mellon Research shows self-affirmation improves problem-solving under stress
11. How Weight-Loss Surgery Improves Diabetes Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: